Answers are grounded in this paper and cite their sources.
The gut microbiota is a major contributor to alcohol-associated liver disease (ALD) progression via the gut–liver axis. Bacteroides thetaiotaomicron ( B. theta ) is a key intestinal commensal that regulates interactions between immune cells and intestinal epithelial cells (IECs). B. theta produces multiple capsular polysaccharides (CPSs), cell-surface structures that modulate host immunity. Group 3 innate lymphoid cells (ILC3s) maintain gut barrier integrity by producing IL-22, a cytokine that protects against alcohol-induced liver injury. Here, we tested the hypothesis that B. theta and its CPSs attenuate ALD by regulating IEC–immune cell crosstalk. Using CPS-deficient and single CPS-expressing B. theta strains, we demonstrate that B. theta -derived CPSs, particularly CPS5, attenuate ethanol-induced liver steatosis by promoting IL-22-producing ILC3 responses. Mechanistically, CPS-dependent utilization of the dietary glycan fucose enhanced B. theta colonization and increased butyrate production, which activated epithelial aryl hydrocarbon receptor (AHR) signaling and promoted IL-23 expression, leading to the expansion of IL-22-producing ILC3s. Consequently, combined treatment with B. theta and fucose not only ameliorated hepatic steatosis but also protected against alcohol-induced liver injury. Furthermore, the protective effects of butyrate and B. theta plus fucose were dependent on the epithelial AHR–ILC3 axis. Collectively, these findings identify a CPS5–butyrate–AHR–ILC3/IL-22 pathway through which B. theta and dietary fucose enhance intestinal barrier function and protect against ALD, highlighting a potential microbiome-based therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Sriwastva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: